Programa de Pós-Graduação em Epidemiologia, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Programa de Pós-Graduação em Epidemiologia, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Eur J Hosp Pharm. 2021 Jan;28(1):4-9. doi: 10.1136/ejhpharm-2019-002111. Epub 2020 Feb 10.
The prevalence of drug-drug interactions (DDIs) in hospital settings is variable, and elderly patients are considered a high risk population for DDIs. There are no systematic reviews describing the prevalence of DDIs in hospitalised elderly patients.
To assess and summarise the available data on the prevalence of DDIs in hospitalised elderly patients and to describe which drugs, drug classes and drug combinations are most commonly involved in DDIs.
A systematic electronic literature search was conducted on Medline/PubMed, Embase, Lilacs, SciElo, Web of Science, Cinahl, Scopus, Cochrane, OpenGrey, Capes Thesis Bank, OasisBR, OpenAire and abstracts from scientific events, without limitation on language or period of publication. Study selection was completed on 21 September 2018.
STUDY ELIGIBILITY CRITERIA, PARTICIPANTS AND INTERVENTIONS: Original observational studies that reported the prevalence of actual or potential DDIs during hospitalisation in patients aged 60 years or older were included. The main outcome measure was prevalence of DDIs and number of DDIs per patient. Subgroup analysis was performed in studies that reported the prevalence of DDIs in geriatric units.
Study quality was assessed using the Agency for Healthcare Research and Quality methodological checklist for cross sectional and prevalence studies.
34 studies were included, involving 9577 patients. The prevalence of DDIs ranged from 8.34% to 100%. In studies conducted in geriatric units, the prevalence ranged from 80.5% to 90.5%. The number of DDIs per patient ranged from 1.2 to 30.6. Single drugs most commonly involved in DDIs were furosemide, captopril, warfarin and dipyrone. Drug classes mostly involved were potassium sparing diuretics and angiotensin converting enzyme inhibitors.
The main limitation is the heterogeneity between the included studies that precluded a meta-analysis. Several different methods were used to identify DDIs, majorly, and potential DDIs. Few studies have reported measures to control the quality of the collected data.
The prevalence of DDIs ranged widely, and the variation may reflect differences in the conditions of the elderly patients and level of attention (or complexity of care), as well as methodological differences, especially the methods and/or software used to identify DDIs.
CRD42018096720.
药物-药物相互作用(DDI)在医院环境中的发生率是可变的,老年人被认为是 DDI 的高风险人群。目前尚无系统评价描述住院老年患者 DDI 的发生率。
评估和总结住院老年患者 DDI 发生率的现有数据,并描述哪些药物、药物类别和药物组合最常涉及 DDI。
系统地检索了 Medline/PubMed、Embase、Lilacs、SciELO、Web of Science、CINHAL、Scopus、Cochrane、OpenGrey、Capes 论文库、OasisBR、OpenAire 和科学活动的摘要,无语言或出版时间限制。研究选择于 2018 年 9 月 21 日完成。
研究入选标准、参与者和干预措施:纳入了报告 60 岁及以上住院患者实际或潜在 DDI 发生率的原始观察性研究。主要结局指标为 DDI 的发生率和每位患者的 DDI 数量。在报告老年病房 DDI 发生率的研究中进行了亚组分析。
使用医疗保健研究和质量机构横断面和流行率研究的方法检查表评估研究质量。
纳入了 34 项研究,涉及 9577 名患者。DDI 的发生率从 8.34%到 100%不等。在老年病房进行的研究中,发生率从 80.5%到 90.5%不等。每位患者的 DDI 数量从 1.2 到 30.6 不等。最常涉及的单药是呋塞米、卡托普利、华法林和双氯芬酸。最常涉及的药物类别是保钾利尿剂和血管紧张素转换酶抑制剂。
主要的局限性是纳入的研究之间存在很大的异质性,这使得无法进行荟萃分析。识别 DDI 的方法很多,主要是潜在的 DDI。很少有研究报告了控制收集数据质量的措施。
DDI 的发生率差异很大,这种差异可能反映了老年患者的病情和关注度(或护理的复杂性)以及方法学差异,特别是识别 DDI 的方法和/或软件的差异。
CRD42018096720。